{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:00Z","timestamp":1788306540345,"version":"build-2803163510"},"reference-count":22,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"abstract":"<jats:p>COVID-19 is a concerning global pandemic. Common manifestations are fever and respiratory symptoms. In addition, recent studies reported dermatological manifestations as extrapulmonary signs. One of these is telogen effluvium which is related to post COVID-19 comorbidities. The aim of this study was to assess the prevalence of telogen effluvium among COVID-19 patients. This observational cross-sectional study included 198 patients who were admitted for COVID-19. The PCR test was performed to detect positive cases. After discharge, all patients were interviewed about hair loss. Of these patients, 79 were male (39.9%), and 119 were female (60.1%). The age ranged from 18 to 85 years old. 48 patients showed hair loss. Telogen effluvium (TE) is one of the consequences of the COVID-19 pandemic. COVID-19 leads to more medications and stress situations, which trigger TE.<\/jats:p>","DOI":"10.25122\/jml-2021-0380","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T09:33:48Z","timestamp":1668677628000},"page":"631-634","source":"Crossref","is-referenced-by-count":25,"title":["Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity"],"prefix":"10.25122","volume":"15","author":[{"given":"Shahram","family":"Seyfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"1. Department of Anesthesiology, Babol University of Medical Sciences, Babol, Iran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robabeh","family":"Alijanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"2. Iranian Medical Laser Association, Babol, Iran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Robabeh Alijanpour, Iranian Medical Laser Association, Babol, Iran. E-mail: dr_r.alijanpour@yahoo.com","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Aryanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"3. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Ezoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"4. Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"5. Clinical Research Development, Unit of Ayatollah Rohani Hospital, Babol University of Medical Sciences, Babol, Iran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","published-online":{"date-parts":[[2022,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, et al. Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. Dermatol Ther. 2020 Nov;33(6):e13986. doi: 10.1111\/dth.13986.","DOI":"10.1111\/dth.13986"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID-19 emergency: Psychological implications. Dermatol Ther. 2020 Jul;33(4):e13648. doi: 10.1111\/dth.13648.","DOI":"10.1111\/dth.13648"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Grover C, Khurana A. Telogen effluvium. Indian J Dermatol Venereol Leprol 2013;79:591-603. doi: 10.4103\/0378-6323.116731.","DOI":"10.4103\/0378-6323.116731"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Limburg H, Harbig A, Bestle D, Stein DA, et al. TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes. J Virol. 2019 Oct 15;93(21):e00649-19. doi: 10.1128\/JVI.00649-19.","DOI":"10.1128\/JVI.00649-19"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Lucas JM, Heinlein C, Kim T, Hernandez SA, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158\/2159-8290.CD-13-1010.","DOI":"10.1158\/2159-8290.CD-13-1010"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Tolouian R, Tolouian A, Ardalan M. Blocking serine protease (TMPRSS2) by Bromhexine; looking at potential treatment to prevent COVID-19 infection. Marshall J Med. 2020;6(3):11. doi: 10.33470\/2379-9536.1286.","DOI":"10.33470\/2379-9536.1286"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27;12(5):e8320. doi: 10.7759\/cureus.8320.","DOI":"10.7759\/cureus.8320"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Alijanpour R, Aliakbarpour F. A randomized clinical trial on the comparison between hair shaving and snipping prior to laser hair removal sessions in women suffering from hirsutism. J Cosmet Dermatol. 2017 Mar;16(1):70-75. doi: 10.1111\/jocd.12280.","DOI":"10.1111\/jocd.12280"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. Alijanpour R, Poorsattar Bejeh Mir A. The Effect of Topical Glycerol Trinitrate on Laser-Aided Facial Hair Removal: A Triple-Blinded Randomized Clinical Trial. Photomed Laser Surg. 2015 Dec;33(12):592-7. doi: 10.1089\/pho.2015.3881.","DOI":"10.1089\/pho.2015.3881"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Olds H, Liu J, Luk K, Lim HW, et al. Telogen effluvium associated with COVID-19 infection. Dermatol Ther. 2021 Mar;34(2):e14761. doi: 10.1111\/dth.14761.","DOI":"10.1111\/dth.14761"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Akta\u015f H, Hamidi AA. Urticaria in a patient with COVID-19: Therapeutic and diagnostic difficulties. Dermatol Ther. 2020 Jul;33(4):e13610. doi: 10.1111\/dth.13610.","DOI":"10.1111\/dth.13610"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Galv\u00e1n Casas C, Catal\u00e0 A, Carretero Hern\u00e1ndez G, Rodr\u00edguez-Jim\u00e9nez P, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020 Jul;183(1):71-77. doi: 10.1111\/bjd.19163.","DOI":"10.1111\/bjd.19163"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Di Landro A, Naldi L, Glaser E, Paus R, Tosti A. Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients. Exp Dermatol. 2021 Jul;30(7):999-1000. doi: 10.1111\/exd.14352.","DOI":"10.1111\/exd.14352"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Ito T, Ito N, Saathoff M, Bettermann A, et al. Interferon-gamma is a potent inducer of catagen-like changes in cultured human anagen hair follicles. Br J Dermatol. 2005 Apr;152(4):623-31. doi: 10.1111\/j.1365-2133.2005.06453.x.","DOI":"10.1111\/j.1365-2133.2005.06453.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016\/S2213-2600(20)30216-2.","DOI":"10.1016\/S2213-2600(20)30216-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Tufan A, Avano\u011flu G\u00fcler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632. doi: 10.3906\/sag-2004-168.","DOI":"10.3906\/sag-2004-168"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Gupta G, Singh Y, Chellappan D, Dua K. Emerging dermatological symptoms in coronavirus pandemic. J Cosmet Dermatol. 2020;19(9):2447-2448. doi: 10.1111\/jocd.13466.","DOI":"10.1111\/jocd.13466"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Goldust M, Kroumpouzos G, Murrell DF, Jafferany M, et al. Use of face masks in dermatology department during the COVID-19 outbreak. Dermatol Ther. 2020 Sep;33(5):e13521. doi: 10.1111\/dth.13521.","DOI":"10.1111\/dth.13521"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Shome D, Kapoor R, Surana M, Vadera S, Shah R. Efficacy of QR678 Neo\u00ae hair growth factor formulation for the treatment of hair loss in Covid-19-induced persistent Telogen Effluvium-A prospective, clinical, single-blind study. J Cosmet Dermatol. 2022 Jan;21(1):16-23. doi: 10.1111\/jocd.14626.","DOI":"10.1111\/jocd.14626"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Ir J Med Sci. 2021 Aug 31:1\u20135. doi: 10.1007\/s11845-021-02754-5.","DOI":"10.1007\/s11845-021-02754-5"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Hussain N, Agarwala P, Iqbal K, Omar HMS, et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J Med Virol. 2022 Apr;94(4):1391-1401. doi: 10.1002\/jmv.27534.","DOI":"10.1002\/jmv.27534"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Kutlu \u00d6. Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of the COVID-19 pandemic. Dermatol Ther. 2020 Nov;33(6):e13949. doi: 10.1111\/dth.1394.","DOI":"10.1111\/dth.13949"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/JMedLife-15-631.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T09:33:57Z","timestamp":1668677637000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/JMedLife-15-631.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["JMedLife-15-631"],"URL":"https:\/\/doi.org\/10.25122\/jml-2021-0380","relation":{},"ISSN":["1844-122X","1844-3117"],"issn-type":[{"value":"1844-122X","type":"print"},{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}